Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
Limited antiretroviral treatment regimens in resource-limited settings require long-term sustainability of patients on the few available options. We evaluated the incidence and predictors of combined antiretroviral treatment (cART) modifications, in an outpatient cohort of 955 patients who initiated...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3973699?pdf=render |
id |
doaj-37edc4fa28c742dbae2700fc0ad2ecbe |
---|---|
record_format |
Article |
spelling |
doaj-37edc4fa28c742dbae2700fc0ad2ecbe2020-11-25T02:15:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0194e9310610.1371/journal.pone.0093106Incidence and predictors of first line antiretroviral regimen modification in western Kenya.Seth InzauleJuliana OtienoJoan KalyangoLillian NafisaCharles KabugoJosephine NalusibaDaniel KwaroClement ZehCharles KaramagiLimited antiretroviral treatment regimens in resource-limited settings require long-term sustainability of patients on the few available options. We evaluated the incidence and predictors of combined antiretroviral treatment (cART) modifications, in an outpatient cohort of 955 patients who initiated cART between January 2009 and January 2011 in western Kenya.cART modification was defined as either first time single drug substitution or switch. Incidence rates were determined by Poisson regression and risk factor analysis assessed using multivariate Cox regression modeling.Over a median follow-up period of 10.7 months, 178 (18.7%) patients modified regimens (incidence rate (IR); 18.6 per 100 person years [95% CI: 16.2-21.8]). Toxicity was the most common cited reason (66.3%). In adjusted multivariate Cox piecewise regression model, WHO disease stage III/IV (aHR; 1.82, 95%CI: 1.25-2.66), stavudine (d4T) use (aHR; 2.21 95%CI: 1.49-3.30) and increase in age (aHR; 1.02, 95%CI: 1.0-1.04) were associated with increased risk of treatment modification within the first year post-cART. Zidovudine (AZT) and tenofovir (TDF) use had a reduced risk for modification (aHR; 0.60 95%CI: 0.38-0.96 and aHR; 0.51 95%CI: 0.29-0.91 respectively). Beyond one year of treatment, d4T use (aHR; 2.75, 95% CI: 1.25-6.05), baseline CD4 counts ≤350 cells/mm3 (aHR; 2.45, 95%CI: 1.14-5.26), increase in age (aHR; 1.05 95%CI: 1.02-1.07) and high baseline weight >60kg aHR; 2.69 95% CI: 1.58-4.59) were associated with risk of cART modification.Early treatment initiation at higher CD4 counts and avoiding d4T use may reduce treatment modification and subsequently improve sustainability of patients on the available limited options.http://europepmc.org/articles/PMC3973699?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Seth Inzaule Juliana Otieno Joan Kalyango Lillian Nafisa Charles Kabugo Josephine Nalusiba Daniel Kwaro Clement Zeh Charles Karamagi |
spellingShingle |
Seth Inzaule Juliana Otieno Joan Kalyango Lillian Nafisa Charles Kabugo Josephine Nalusiba Daniel Kwaro Clement Zeh Charles Karamagi Incidence and predictors of first line antiretroviral regimen modification in western Kenya. PLoS ONE |
author_facet |
Seth Inzaule Juliana Otieno Joan Kalyango Lillian Nafisa Charles Kabugo Josephine Nalusiba Daniel Kwaro Clement Zeh Charles Karamagi |
author_sort |
Seth Inzaule |
title |
Incidence and predictors of first line antiretroviral regimen modification in western Kenya. |
title_short |
Incidence and predictors of first line antiretroviral regimen modification in western Kenya. |
title_full |
Incidence and predictors of first line antiretroviral regimen modification in western Kenya. |
title_fullStr |
Incidence and predictors of first line antiretroviral regimen modification in western Kenya. |
title_full_unstemmed |
Incidence and predictors of first line antiretroviral regimen modification in western Kenya. |
title_sort |
incidence and predictors of first line antiretroviral regimen modification in western kenya. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
Limited antiretroviral treatment regimens in resource-limited settings require long-term sustainability of patients on the few available options. We evaluated the incidence and predictors of combined antiretroviral treatment (cART) modifications, in an outpatient cohort of 955 patients who initiated cART between January 2009 and January 2011 in western Kenya.cART modification was defined as either first time single drug substitution or switch. Incidence rates were determined by Poisson regression and risk factor analysis assessed using multivariate Cox regression modeling.Over a median follow-up period of 10.7 months, 178 (18.7%) patients modified regimens (incidence rate (IR); 18.6 per 100 person years [95% CI: 16.2-21.8]). Toxicity was the most common cited reason (66.3%). In adjusted multivariate Cox piecewise regression model, WHO disease stage III/IV (aHR; 1.82, 95%CI: 1.25-2.66), stavudine (d4T) use (aHR; 2.21 95%CI: 1.49-3.30) and increase in age (aHR; 1.02, 95%CI: 1.0-1.04) were associated with increased risk of treatment modification within the first year post-cART. Zidovudine (AZT) and tenofovir (TDF) use had a reduced risk for modification (aHR; 0.60 95%CI: 0.38-0.96 and aHR; 0.51 95%CI: 0.29-0.91 respectively). Beyond one year of treatment, d4T use (aHR; 2.75, 95% CI: 1.25-6.05), baseline CD4 counts ≤350 cells/mm3 (aHR; 2.45, 95%CI: 1.14-5.26), increase in age (aHR; 1.05 95%CI: 1.02-1.07) and high baseline weight >60kg aHR; 2.69 95% CI: 1.58-4.59) were associated with risk of cART modification.Early treatment initiation at higher CD4 counts and avoiding d4T use may reduce treatment modification and subsequently improve sustainability of patients on the available limited options. |
url |
http://europepmc.org/articles/PMC3973699?pdf=render |
work_keys_str_mv |
AT sethinzaule incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya AT julianaotieno incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya AT joankalyango incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya AT lilliannafisa incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya AT charleskabugo incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya AT josephinenalusiba incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya AT danielkwaro incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya AT clementzeh incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya AT charleskaramagi incidenceandpredictorsoffirstlineantiretroviralregimenmodificationinwesternkenya |
_version_ |
1724896287557419008 |